The Italian real-life post-stroke spasticity survey: unmet needs in the management of spasticity with botulinum toxin type A

A Picelli, A Baricich, C Cisari, Stefano Paolucci, Nicola Smania, Giorgio Sandrini

Research output: Contribution to journalArticle

Abstract

The present national survey seeking to identify unmet needs in the management of spasticity with botulinum toxin type A focused on the use of OnabotulinumoxinA, since this is the brand with the widest range of licensed indications in Italy. Physicians from twenty-four Italian neurorehabilitation units compiled a questionnaire about "real-life" post-stroke spasticity management. OnabotulinumtoxinA was reported to be used in the following average doses: upper limb 316.7 ± 79.1 units; lower limb 327.8 ± 152.3; upper and lower limb 543.7 ± 123.7 units. Of the physicians surveyed, 37.5% felt that increasing the frequency of OnabotulinumtoxinA injection would improve its efficacy; 70.8% use electrical stimulation/electromyography guidance (one fourth of injections with no instrumental guidance). Instrumental evaluation was used by 41.7% of the physicians. The participants expressed the view that early identification of post-stroke spasticity would be facilitated by the availability of a post-stroke checklist, and that this should be used by physiotherapists (91.7%), physiatrists (58.3%), family doctors (50%), stroke unit physicians (25%), patients and caregivers (79.2%). According to our findings, the management of poststroke spasticity has several unmet needs that, were they addressed, might improve these patients' clinical outcomes and quality of life. These needs concern patient follow-up, where a clearly defined pathway is lacking; furthermore, there is a need to use maximum doses per treatment and to ensure early intervention on post-stroke spasticity.

Original languageEnglish
Pages (from-to)89-96
Number of pages8
JournalFunctional Neurology
Volume32
Issue number2
Publication statusPublished - Jul 6 2017

Fingerprint

Type A Botulinum Toxins
Stroke
Physicians
Lower Extremity
Injections
Physical Therapists
Electromyography
Checklist
Upper Extremity
Italy
Caregivers
Electric Stimulation
Quality of Life
Surveys and Questionnaires

Keywords

  • Botulinum Toxins, Type A
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Italy
  • Longitudinal Studies
  • Lower Extremity
  • Male
  • Muscle Spasticity
  • Neuromuscular Agents
  • Patient Satisfaction
  • Quality of Life
  • Retrospective Studies
  • Stroke
  • Stroke Rehabilitation
  • Surveys and Questionnaires
  • Upper Extremity
  • Journal Article

Cite this

The Italian real-life post-stroke spasticity survey : unmet needs in the management of spasticity with botulinum toxin type A. / Picelli, A; Baricich, A; Cisari, C; Paolucci, Stefano; Smania, Nicola; Sandrini, Giorgio.

In: Functional Neurology, Vol. 32, No. 2, 06.07.2017, p. 89-96.

Research output: Contribution to journalArticle

Picelli, A ; Baricich, A ; Cisari, C ; Paolucci, Stefano ; Smania, Nicola ; Sandrini, Giorgio. / The Italian real-life post-stroke spasticity survey : unmet needs in the management of spasticity with botulinum toxin type A. In: Functional Neurology. 2017 ; Vol. 32, No. 2. pp. 89-96.
@article{61ef34e1468244debb9a1eccbb4a6406,
title = "The Italian real-life post-stroke spasticity survey: unmet needs in the management of spasticity with botulinum toxin type A",
abstract = "The present national survey seeking to identify unmet needs in the management of spasticity with botulinum toxin type A focused on the use of OnabotulinumoxinA, since this is the brand with the widest range of licensed indications in Italy. Physicians from twenty-four Italian neurorehabilitation units compiled a questionnaire about {"}real-life{"} post-stroke spasticity management. OnabotulinumtoxinA was reported to be used in the following average doses: upper limb 316.7 ± 79.1 units; lower limb 327.8 ± 152.3; upper and lower limb 543.7 ± 123.7 units. Of the physicians surveyed, 37.5{\%} felt that increasing the frequency of OnabotulinumtoxinA injection would improve its efficacy; 70.8{\%} use electrical stimulation/electromyography guidance (one fourth of injections with no instrumental guidance). Instrumental evaluation was used by 41.7{\%} of the physicians. The participants expressed the view that early identification of post-stroke spasticity would be facilitated by the availability of a post-stroke checklist, and that this should be used by physiotherapists (91.7{\%}), physiatrists (58.3{\%}), family doctors (50{\%}), stroke unit physicians (25{\%}), patients and caregivers (79.2{\%}). According to our findings, the management of poststroke spasticity has several unmet needs that, were they addressed, might improve these patients' clinical outcomes and quality of life. These needs concern patient follow-up, where a clearly defined pathway is lacking; furthermore, there is a need to use maximum doses per treatment and to ensure early intervention on post-stroke spasticity.",
keywords = "Botulinum Toxins, Type A, Dose-Response Relationship, Drug, Female, Humans, Italy, Longitudinal Studies, Lower Extremity, Male, Muscle Spasticity, Neuromuscular Agents, Patient Satisfaction, Quality of Life, Retrospective Studies, Stroke, Stroke Rehabilitation, Surveys and Questionnaires, Upper Extremity, Journal Article",
author = "A Picelli and A Baricich and C Cisari and Stefano Paolucci and Nicola Smania and Giorgio Sandrini",
year = "2017",
month = "7",
day = "6",
language = "English",
volume = "32",
pages = "89--96",
journal = "Functional Neurology",
issn = "0393-5264",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "2",

}

TY - JOUR

T1 - The Italian real-life post-stroke spasticity survey

T2 - unmet needs in the management of spasticity with botulinum toxin type A

AU - Picelli, A

AU - Baricich, A

AU - Cisari, C

AU - Paolucci, Stefano

AU - Smania, Nicola

AU - Sandrini, Giorgio

PY - 2017/7/6

Y1 - 2017/7/6

N2 - The present national survey seeking to identify unmet needs in the management of spasticity with botulinum toxin type A focused on the use of OnabotulinumoxinA, since this is the brand with the widest range of licensed indications in Italy. Physicians from twenty-four Italian neurorehabilitation units compiled a questionnaire about "real-life" post-stroke spasticity management. OnabotulinumtoxinA was reported to be used in the following average doses: upper limb 316.7 ± 79.1 units; lower limb 327.8 ± 152.3; upper and lower limb 543.7 ± 123.7 units. Of the physicians surveyed, 37.5% felt that increasing the frequency of OnabotulinumtoxinA injection would improve its efficacy; 70.8% use electrical stimulation/electromyography guidance (one fourth of injections with no instrumental guidance). Instrumental evaluation was used by 41.7% of the physicians. The participants expressed the view that early identification of post-stroke spasticity would be facilitated by the availability of a post-stroke checklist, and that this should be used by physiotherapists (91.7%), physiatrists (58.3%), family doctors (50%), stroke unit physicians (25%), patients and caregivers (79.2%). According to our findings, the management of poststroke spasticity has several unmet needs that, were they addressed, might improve these patients' clinical outcomes and quality of life. These needs concern patient follow-up, where a clearly defined pathway is lacking; furthermore, there is a need to use maximum doses per treatment and to ensure early intervention on post-stroke spasticity.

AB - The present national survey seeking to identify unmet needs in the management of spasticity with botulinum toxin type A focused on the use of OnabotulinumoxinA, since this is the brand with the widest range of licensed indications in Italy. Physicians from twenty-four Italian neurorehabilitation units compiled a questionnaire about "real-life" post-stroke spasticity management. OnabotulinumtoxinA was reported to be used in the following average doses: upper limb 316.7 ± 79.1 units; lower limb 327.8 ± 152.3; upper and lower limb 543.7 ± 123.7 units. Of the physicians surveyed, 37.5% felt that increasing the frequency of OnabotulinumtoxinA injection would improve its efficacy; 70.8% use electrical stimulation/electromyography guidance (one fourth of injections with no instrumental guidance). Instrumental evaluation was used by 41.7% of the physicians. The participants expressed the view that early identification of post-stroke spasticity would be facilitated by the availability of a post-stroke checklist, and that this should be used by physiotherapists (91.7%), physiatrists (58.3%), family doctors (50%), stroke unit physicians (25%), patients and caregivers (79.2%). According to our findings, the management of poststroke spasticity has several unmet needs that, were they addressed, might improve these patients' clinical outcomes and quality of life. These needs concern patient follow-up, where a clearly defined pathway is lacking; furthermore, there is a need to use maximum doses per treatment and to ensure early intervention on post-stroke spasticity.

KW - Botulinum Toxins, Type A

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Italy

KW - Longitudinal Studies

KW - Lower Extremity

KW - Male

KW - Muscle Spasticity

KW - Neuromuscular Agents

KW - Patient Satisfaction

KW - Quality of Life

KW - Retrospective Studies

KW - Stroke

KW - Stroke Rehabilitation

KW - Surveys and Questionnaires

KW - Upper Extremity

KW - Journal Article

M3 - Article

C2 - 28676142

VL - 32

SP - 89

EP - 96

JO - Functional Neurology

JF - Functional Neurology

SN - 0393-5264

IS - 2

ER -